| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-09-18 | Xbiotech (USA - TX) US Oncology Research | Xilonix™ | colorectal cancer | collaboration clinical research |
Cancer - Oncology | Collaboration agreement |
| 2013-09-16 | Horizon Discovery (UK) Harvard University (USA) | CRISPR gene editing technology | licensing |
Technology - Services | Licensing agreement | |
| 2013-09-16 | Affimed Therapeutics (Germany) The Leukemia & Lymphoma Society (USA) | AFM13 | Hodgkin lymphoma | collaboration |
Cancer - Oncology | Clinical research agreement |
| 2013-09-16 | Teva Pharmaceuticals (Israel) Cancer Research Technology - CRT (UK) | cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-09-16 | ImmunoGenes (Switzerland - Hungary) Massachusetts General Hospital (USA - MA) | antibodies | hematological cancers | development |
Cancer - Oncology | Development agreement |
| 2013-09-16 | Sigma-Tau PharmaSource, subsidiary of Sigma-Tau Pharmaceuticals (USA - Italy) Aradigm Corporation (USA) | Pulmaquin® (inhaled ciprofloxacin) | severe respiratory diseases, including non-cystic fibrosis bronchiectasis | Respiratory diseases - Rare diseases - Genetic diseases | Production agreement | |
| 2013-09-13 | Servier (France) Shanghai Institute of Materia Medica, Chinese Academy of Sciences, (SIMM) | lucitanib | collaboration |
Cancer - Oncology | Licensing agreement | |
| 2013-09-12 | Evotec (Germany) Harvard Stem Cell Institute (USA - MA) | compounds that prevent or slow down the loss of motor neurons | amyotrophic lateral sclerosis | R&D |
Neurodegenerative diseases - Rare diseases | R&D agreement |
| 2013-09-11 | Cell Therapy Catapult (UK) Roslin Cells (UK) | pluripotent stem cells bank | collaboration |
Technology - Services - Regenerative medicine | Production agreement | |
| 2013-09-11 | AstraZeneca (UK) Merck&Co (USA) | MK-1775 | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-09-11 | CELLforCURE (France) Héma-Québec (Canada) | advanced-therapy medicinal products | collaboration |
Regenerative medicine | Collaboration agreement | |
| 2013-09-10 | Medicyte (Germany) Sernova (Canada) | upcyte® cells - Sernova\'s Cell Pouch™ | hemophilia A | collaboration |
Rare diseases - Genetic diseases - Hematological diseases | Collaboration agreement |
| 2013-09-10 | AstraZeneca (UK) Hadasit (Israel) | cancer, respiratory diseases, diabetes | R&D |
Cancer - Oncology - Respiratory diseases - Metabolic diseases | R&D agreement | |
| 2013-09-09 | Swedish Orphan Biovitrum - Sobi (Sweden) Amgen (USA) | Kineret® and additional clinical data for Kepivance® | rheumatoid arthritis and all therapeutic indications | commercialisation |
Rare diseases - Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Commercialisation agreement |
| 2013-09-09 | Oncodesign (France) Banook Central Imaging (France) | pharmaco-imaging services and tools | collaboration |
Technology - Services | Collaboration agreement | |
| 2013-09-06 | Novartis (Switzerland) Regenerex (USA) | Facilitating Cell Therapy (FCRx) platform | R&D |
Transplantation | Licensing agreement | |
| 2013-09-06 | Medivir (Sweden) Daewoong Pharmaceutical (South Korea) | MIV-210 (lagociclovir valactate) | hepatitis B | development |
Infectious diseases | Development agreement |
| 2013-09-05 | Go To Market Consulting (USA) Debiopharm (Switzerland) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2013-09-03 | Santhera Pharmaceuticals (Switzerland) Takeda Pharmaceutical (Japan) | Catena® (idebenone) | Duchenne muscular dystrophy | licensing |
Rare diseases - Neuromuscular diseases | Licensing agreement |
| 2013-09-03 | MDX Health (Belgium) - Stratose (USA) | ConfirmMDx™ for prostate cancer test | prostate cancer | commercialisation |
Cancer - Oncology | Commercialisation agreement |
